The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare ...

The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and ...

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.